ROCKVILLE, Md., Feb. 24, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX ) today announced positive interim data from the Phase I/II trial of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I). Data from the Phase I/II trial and single-patient Investigational New Drug (IND) application of RGX-111 were presented by Ray Wang, M.D., Campbell Foundation Director of the Multidisciplinary Lysosomal Program, Division of Metabolic Disorders, CHOC Children's Hospital, Department of Pediatrics, University of California, Irvine, at the 19 th Annual WORLD Symposium ™.